FOSUN HEALTH Logo

Lupus Nephritis Diagnosis

catalogue

Lupus Nephritis Diagnosis

Lupus Nephritis Diagnosis

Diagnosis in lupus nephritis has two layers. The first establishes that the kidney is involved at all, and it is made from urine and blood tests. The second establishes what the involvement actually is, and it is made from a kidney biopsy. The biopsy is the layer that people find hardest to accept, and it is also the layer that decides the treatment — which is why it is standard here rather than reserved for difficult cases.

Why the biopsy is the centre of the assessment

Blood and urine can tell you that the kidney is involved and how much it is leaking. They cannot tell you what the inflammation is made of, and in lupus nephritis that is the question the treatment is built on. Three things can only be obtained from tissue.

The three questions only a biopsy answers
Question Why it changes what is done
Which class is this? Some classes are managed by treating the lupus rather than the kidney. Others need induction immunosuppression. The class is the starting point of the plan
How much of it is active? Active inflammation is what responds to treatment. Its extent tells you how hard to push, and it gives you a baseline to judge the response against
How much is already scar? Scar does not respond, and heavy immunosuppression given for scar is risk without benefit. Its extent is what stops treatment from escalating when it should not

The procedure itself is short. A needle is passed into the kidney under imaging guidance, usually taking two small cores of tissue, which are examined by light microscopy, immunofluorescence and electron microscopy. Because bleeding is the main risk, the biopsy is preceded by checks of blood pressure, clotting and blood counts, and by a review of anything that increases bleeding — including anti-inflammatory painkillers and blood thinners — so that these can be adjusted in advance. Most people are observed for several hours afterwards and go home the same day or the next.

One honest qualification, because it matters for decisions rather than for reassurance: a biopsy is not always possible. Serious bleeding risk, uncontrolled blood pressure, a single working kidney where the risk is judged unacceptable, or a person who declines it are all situations where treatment is started from the clinical picture instead. That is a considered fallback rather than an equivalent route, and it is documented as such.

How each class changes the treatment

The classification is descriptive rather than a ranking of how unwell someone is, but each pattern has a usual position on how much treatment it warrants. The table below is that correspondence, not a substitute for reading your own report with your own clinician.

Class, and how it usually positions the treatment
Class Usual position on treatment What to watch for
Class I Treatment is directed at the lupus rather than at the kidney, with monitoring of the urine Not a reason to stop monitoring: the class can change over time
Class II Usually mild; kidney-directed immunosuppression is often not required Blood pressure and protein still have to be managed, and activity elsewhere still treated
Class III Induction treatment, with strength set by how much of the lesion is active A combined class III plus V behaves differently from class III alone and should be treated as a proliferative lesion
Class IV The most actively treated class: induction followed by a long maintenance period Segmental and global patterns are both class IV; what varies is the proportion of active and chronic change
Class V Driven by how much protein is being lost, and by whether a proliferative class is present alongside A pure membranous pattern with modest protein may be watched; heavy protein loss or a combined class changes the decision
Class VI Immunosuppression generally steps back, because most of the filtering units are already scarred Care turns to protecting what remains and planning replacement — and to being explicit that the aim has changed

Two further points belong with this table. First, a class can be reported with a combination — class III plus V, or IV plus V — and combinations take the treatment of the proliferative component, because it is the proliferative component that threatens the kidney. Second, a class can transform between biopsies, which is why a change in the clinical course is a reason to reconsider the tissue rather than to continue on an earlier report indefinitely.

Active or scarred — the distinction that decides how far to go

Two features are scored separately on every biopsy: an activity index, describing injury that is fresh, and a chronicity index, describing injury that has already turned to scar. The distinction is not academic. It is what tells a clinician whether to escalate, to hold, or to step back.

What counts as active, and what counts as chronic
Active change — responds to treatment Chronic change — does not respond
Increase in cells within the filtering tuft Filtering units already replaced by scar
Karyorrhexis and necrosis of the tuft Crescents that have become fibrous rather than cellular
Cellular crescents Scarring between the tubules, and wasting of the tubules themselves
Deposits beneath the lining of the capillaries Thickening of the small vessel walls after long-standing damage

The practical consequences run in both directions. Where activity dominates and chronicity is limited, escalation is worth it, because there is something to save and something to gain. Where chronicity dominates, more immunosuppression generally does not restore function and adds infection risk, so the aim shifts to protecting what remains, controlling blood pressure and protein, and planning ahead. And where both are present together, the balance is a matter of judgement — which is exactly the situation in which a second opinion has something to offer.

A partial response is not a failure. Treatment of lupus nephritis is judged over months, against targets agreed at the outset, and the shape of the response over time is read together with the biopsy findings rather than instead of them.

What the blood tests add, and what they cannot tell you

The blood tests are how the disease is tracked between biopsies. They are sensitive and they move early, but each has a limitation worth knowing, because it is the limitations that explain why a biopsy is still needed.

Each blood test and its limitation
Test What it shows — and what it cannot
Complement C3 and C4 Falls as immune activity consumes complement, often before symptoms. It reflects activity elsewhere in the body too, not only in the kidney
Anti-dsDNA antibodies Rises with activity in many people and is a useful trend. Some people flare without a rise, and some have high levels without active kidney disease
Antinuclear antibody, anti-Smith Supports the diagnosis of lupus. A positive result does not measure how active the disease is today
Antiphospholipid antibodies Identifies an added risk of clotting, with implications for treatment and for pregnancy. Not a measure of kidney inflammation
Blood counts Low white cells, low platelets and anaemia reflect lupus activity or the effect of treatment — and the two have to be told apart
Inflammatory markers Useful mainly for their negative value: a sharply raised C-reactive protein suggests infection rather than a lupus flare, which changes the whole decision

What no blood test provides is the pattern of injury inside the tissue. That is why complement, antibody and urine results are used to decide when to look, and the biopsy is used to decide what is there.

Monitoring after diagnosis, and when a repeat biopsy is considered

After the diagnosis, the work becomes rhythm rather than investigation. Checks are closer together while the disease is active, most often every one to three months, and spread out to every three to six months once the results have been stable for a sustained period. Each check combines urine, blood and a conversation about lupus activity elsewhere in the body.

What is checked at each visit, and why
At each visit The purpose
Urine sediment and protein measurement Is inflammation active, and is protein falling towards the target agreed at the outset?
Creatinine and filtration rate Is function stable across readings, or is it falling?
Complement and anti-dsDNA Has immune activity changed in a way that predicts a flare?
Blood pressure Is the most modifiable contributor to further damage controlled?
Blood counts and a medicine review Are the medicines doing something they should not, and does the dose still match the disease?
The rest of the body Is there a flare elsewhere — skin, joints, lungs, blood — that the kidney tends to follow?

A repeat biopsy is considered rather than scheduled. The usual triggers are a disease that does not respond as expected, a new flare after a period of remission, or a change in the clinical picture suggesting the pattern has transformed. What a repeat biopsy would change decides whether it is done: if the answer would not alter the treatment, the procedure is not worth its risk.

Frequently Asked Questions

How risky is a kidney biopsy?

It is a routine procedure, and it is not a trivial one, and both of those are true at the same time. A needle is passed into the kidney under imaging guidance, usually taking two small cores of tissue. The commonest complication is bleeding that shows up in the urine for a day or two and settles by itself; a small number of people need observation or a procedure to stop it. Because of that, the biopsy is preceded by a check of your blood pressure, your clotting and your blood counts, and any medicine that increases bleeding — including anti-inflammatory painkillers and blood thinners — is reviewed and adjusted beforehand. The information obtained usually justifies the risk, and where it does not, that is a decision to make with your team rather than alone.

My report says class IV with an activity score. What does that mean?

Two things, and they are read together. The class describes the pattern — where in the filtering unit the inflammation sits and how much of the kidney is involved. The activity and chronicity indices describe what that inflammation is made of: how much of it is fresh, active injury that can be quietened, and how much is already scar that will not respond to anything. So a class IV with a high activity index and a low chronicity index is a disease that is actively damaging the kidney and is likely to respond to treatment. The same class with the emphasis the other way round calls for a different decision, because immunosuppression given for scar adds risk without returning function. Your team should be willing to read the report line by line with you.

Can the blood tests replace the biopsy?

No, and the reason is that they measure different things. Complement and anti-dsDNA tell you how active the immune system is; the urine tells you that something is leaking. Neither can tell you what the inflammation actually looks like in the tissue — which class it is, whether the damage is active or chronic, and what proportion of the filtering units is involved. Those are precisely the questions the treatment is chosen from. Where a biopsy cannot be done, treatment can still be started from the clinical picture, and that is a considered compromise rather than the standard route.

I have already had one biopsy. Will I need another?

Sometimes, and for a specific reason rather than as a routine. A repeat biopsy is most often considered when the disease does not respond as expected to treatment, when a person who had been in remission flares again, or when a change in the clinical picture suggests the pattern may have changed. Lupus nephritis can transform from one class to another, and where that is suspected, treating on the old report means treating a lesion the person may no longer have. The decision is made case by case, weighing what the answer would change.

Find out whether the picture fits, and what the biopsy should be read for

Send your urine and protein results with dates, your creatinine readings if you have more than one, your complement, anti-dsDNA and antibody results, any biopsy report you already hold, and your full medicine list. Our team will return a written opinion on whether a biopsy would change anything at this point, how the class and the activity-chronicity balance should be read, and what can be established from your records before any travel is arranged.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*